Audience

GLP-1 panel (US)

GLP-1 (US): a public Ask Brox audience of Brox clones, each built from a long-form interview with a real person. Every insight fielded on this panel, newest first.

1 insight·0 studies

What did the GLP-1 panel say?

  1. #

    37.5%

    37.5% of weekly GLP-1 injection users (75 of 200) would be likely to switch to a once-daily pill at the same price and the same weight loss; 55.0% would be very unlikely to. — GLP-1 pill or injection? 37.5% of weekly injection users would switch at the same price, and a smaller weight loss cuts that to 17.0%

    base 200

What has Brox published on glp-1 panel (us)?Newest first

What do people ask about glp-1 panel (us)?

Would GLP-1 users switch from an injection to a daily pill at the same price, and what if the pill worked slightly less well?
In September 2026, 37.5% of US weekly GLP-1 injection users (75 of 200, n=200) said they would be likely to switch to a once-daily pill at the same monthly price and the same weight loss, falling to 17.0% if the pill gave about 12% weight loss instead of about 15%.Read the insight

Other audiences

How should you read these findings?

Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.

Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.

What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.

Ask this of your own customers: humans@brox.ai